Sphingosine-1-phosphate receptor subtype 1 activation in the central nervous system contributes to morphine withdrawal in rodents
Opioid therapies for chronic pain are undermined by many adverse side effects that reduce their efficacy and lead to dependence, abuse, reduced quality of life, and even death. We have recently reported that sphingosine-1-phosphate (S1P) 1 receptor (S1PR1) antagonists block the development of morphine-induced hyperalgesia and analgesic tolerance. However, the impact of S1PR1 antagonists on other undesirable side effects of opioids, such as opioid-induced dependence, remains unknown. Here, we demonstrate that naloxone-precipitated morphine withdrawal in mice altered de novo sphingolipid metabolism in the dorsal horn of the spinal cord and increased S1P that accompanied the manifestation of several withdrawal behaviors. Blocking de novo sphingolipid metabolism with intrathecal administration of myriocin, an inhibitor of serine palmitoyltransferase, blocked naloxone-precipitated withdrawal. Noteworthy, we found that competitive (NIBR-15) and functional (FTY720) S1PR1 antagonists attenuated withdrawal behaviors in mice. Mechanistically, at the level of the spinal cord, naloxone-precipitated withdrawal was associated with increased glial activity and formation of the potent inflammatory/neuroexcitatory cytokine interleukin-1β (IL-1β); these events were attenuated by S1PR1 antagonists. These results provide the first molecular insight for the role of the S1P/S1PR1 axis during opioid withdrawal. Our data identify S1PR1 antagonists as potential therapeutics to mitigate opioid-induced dependence and support repurposing the S1PR1 functional antagonist FTY720, which is FDA-approved for multiple sclerosis, as an opioid adjunct.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Journal of neuroinflammation - 17(2020), 1 vom: 22. Okt., Seite 314 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Doyle, Timothy M [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 19.08.2021 Date Revised 19.08.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12974-020-01975-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316615242 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316615242 | ||
003 | DE-627 | ||
005 | 20231225161454.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12974-020-01975-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1055.xml |
035 | |a (DE-627)NLM316615242 | ||
035 | |a (NLM)33092620 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Doyle, Timothy M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sphingosine-1-phosphate receptor subtype 1 activation in the central nervous system contributes to morphine withdrawal in rodents |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.08.2021 | ||
500 | |a Date Revised 19.08.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Opioid therapies for chronic pain are undermined by many adverse side effects that reduce their efficacy and lead to dependence, abuse, reduced quality of life, and even death. We have recently reported that sphingosine-1-phosphate (S1P) 1 receptor (S1PR1) antagonists block the development of morphine-induced hyperalgesia and analgesic tolerance. However, the impact of S1PR1 antagonists on other undesirable side effects of opioids, such as opioid-induced dependence, remains unknown. Here, we demonstrate that naloxone-precipitated morphine withdrawal in mice altered de novo sphingolipid metabolism in the dorsal horn of the spinal cord and increased S1P that accompanied the manifestation of several withdrawal behaviors. Blocking de novo sphingolipid metabolism with intrathecal administration of myriocin, an inhibitor of serine palmitoyltransferase, blocked naloxone-precipitated withdrawal. Noteworthy, we found that competitive (NIBR-15) and functional (FTY720) S1PR1 antagonists attenuated withdrawal behaviors in mice. Mechanistically, at the level of the spinal cord, naloxone-precipitated withdrawal was associated with increased glial activity and formation of the potent inflammatory/neuroexcitatory cytokine interleukin-1β (IL-1β); these events were attenuated by S1PR1 antagonists. These results provide the first molecular insight for the role of the S1P/S1PR1 axis during opioid withdrawal. Our data identify S1PR1 antagonists as potential therapeutics to mitigate opioid-induced dependence and support repurposing the S1PR1 functional antagonist FTY720, which is FDA-approved for multiple sclerosis, as an opioid adjunct | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a GFAP, CD11b, IL-1β | |
650 | 4 | |a Naloxone-precipitated withdrawal | |
650 | 4 | |a Sphingosine-1-phosphate | |
650 | 4 | |a Sphingosine-1-phosphate receptor subtype 1 | |
650 | 7 | |a Analgesics, Opioid |2 NLM | |
650 | 7 | |a Narcotic Antagonists |2 NLM | |
650 | 7 | |a S1pr1 protein, mouse |2 NLM | |
650 | 7 | |a Sphingosine-1-Phosphate Receptors |2 NLM | |
650 | 7 | |a Naloxone |2 NLM | |
650 | 7 | |a 36B82AMQ7N |2 NLM | |
650 | 7 | |a Morphine |2 NLM | |
650 | 7 | |a 76I7G6D29C |2 NLM | |
650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
650 | 7 | |a G926EC510T |2 NLM | |
700 | 1 | |a Hutchinson, Mark R |e verfasserin |4 aut | |
700 | 1 | |a Braden, Kathryn |e verfasserin |4 aut | |
700 | 1 | |a Janes, Kali |e verfasserin |4 aut | |
700 | 1 | |a Staikopoulos, Vicky |e verfasserin |4 aut | |
700 | 1 | |a Chen, Zhoumou |e verfasserin |4 aut | |
700 | 1 | |a Neumann, William L |e verfasserin |4 aut | |
700 | 1 | |a Spiegel, Sarah |e verfasserin |4 aut | |
700 | 1 | |a Salvemini, Daniela |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of neuroinflammation |d 2004 |g 17(2020), 1 vom: 22. Okt., Seite 314 |w (DE-627)NLM149680333 |x 1742-2094 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2020 |g number:1 |g day:22 |g month:10 |g pages:314 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12974-020-01975-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2020 |e 1 |b 22 |c 10 |h 314 |